Loading…
Loading…
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for XBIT and 80,000+ other tickers.
See exactly how XBIT's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for XBIT and 80,000+ other tickers.
XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood…
IND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment
IN8bio (NASDAQ: INAB - Get Free Report) and XBiotech (NASDAQ: XBIT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation. Earnings and Valuation This table compares IN8bio and XBiotech"s
Psyence Biomedical (NASDAQ: PBM - Get Free Report) and XBiotech (NASDAQ: XBIT - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk. Earnings and Valuation This table compares Psyence Biomedical
XBiotech Inc. (NASDAQ: XBIT - Get Free Report) passed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $2.47 and traded as high as $2.68. XBiotech shares last traded at $2.48, with a volume of 87,170 shares changing hands. Analyst Upgrades and Downgrades Separately, Weiss
LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.